Why Mirum Pharmaceuticals Stock Is Back in Focus

Mirum Pharmaceuticals (MIRM) is in the spotlight after its shares rallied 5.5% following positive pivotal phase II data and an FDA priority review for rare disease drug candidate zilurgisertib.

The stock has also logged a 9 day winning streak and a 25% move, lifting Mirum Pharmaceuticals market value to about US$7.3b, which may encourage investors to reassess what is already reflected in the current price.

Beyond the latest trial and FDA update, Mirum Pharmaceuticals has been in a strong upswing, with a 30 day share price return of 25.05% and a year to date share price return of 54.30%. The 1 year total shareholder return of 145.39% and very large 5 year total shareholder return suggest momentum has been building over multiple timeframes.

If this kind of rare disease rally has your attention, it can be useful to widen the lens and review other opportunities in the sector using our screener for 39 healthcare AI stocks

With Mirum Pharmaceuticals trading around US$120.46 after a strong run and sitting at a sizeable discount to the average analyst price target and some intrinsic value estimates, investors now face a key question: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 16.4% Undervalued

Compared with Mirum Pharmaceuticals last close at $120.46, the most followed narrative places fair value at $144.15, implying meaningful upside in its rare disease focus.

Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.

Curious what kind of revenue trajectory, margin shift, and future earnings multiple underpin that fair value for Mirum Pharmaceuticals? The narrative spells out a bold profitability path, rising sales expectations, and a premium valuation framework that many investors may not have fully unpacked yet.

Result: Fair Value of $144.15 (UNDERVALUED)

However, Mirum Pharmaceuticals still faces key risks, including its heavy reliance on LIVMARLI and the possibility that future trial or regulatory outcomes fall short of expectations.

Another View: What Mirum Pharmaceuticals' Sales Multiple Is Telling You

Not everyone will anchor on fair value estimates around $144.15 for Mirum Pharmaceuticals. On sales, the stock trades on a P/S of 12.9x, slightly above the US Biotechs industry at 12.4x and above its own fair ratio of 10.2x, which points to some valuation stretch.

That gap can matter in practice, because it suggests the market is already paying a premium to the level our fair ratio suggests it could drift toward over time. This leaves you to weigh how much execution risk you are comfortable with at this price.

Next Steps

With mixed signals around Mirum Pharmaceuticals and its valuation, you may want to see the full picture for yourself and not just the headline move. Act while sentiment is fresh, review both sides of the story, and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Mirum Pharmaceuticals?

If Mirum Pharmaceuticals has sharpened your interest, do not stop here. Broaden your watchlist with other focused opportunities that could complement your current thinking.

• Target potential mispricing by scanning companies that combine quality fundamentals with attractive valuations using the 41 high quality undervalued stocks.
• Strengthen your portfolio’s income stream by reviewing stocks in the 8 dividend fortresses that offer higher yields with a focus on durability.
• Prioritize resilience by checking companies in the 73 resilient stocks with low risk scores that score well on financial stability and lower overall risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.